Since the beginning of the COVID-19 pandemic, industry and healthcare
providers have investigated methodologies to manage infection of
SARS-CoV-2. One treatment breakthrough has been the introduction of
monoclonal antibodies to prevent worsening SARS-CoV-2 infection in
non-hospitalized patients diagnosed with COVID-19. These monoclonal
antibodies, like bamlanivimab, bind to the SARS-CoV-2 spike protein and
prevent its ability to binding to human ACE2 receptors. This is a case
of a 91 year-old man with no prior seizure history who developed
new-onset seizures after bamlanivimab infusion.